ResearchMoz added Latest Research Report titled " Global Orphan Drugs Market 2017-2021 " to it's Large Report database.
ABSTRACT
About Orphan Drugs
According to Orphan Drug Designation program of the US Food and Drug Administration (FDA), orphan diseases are defined as rare diseases that affects less than 2,00,000 Americans. The global orphan drugs market is expected to benefit from patent extensions like Orphan Drug Exclusivity (ODE), increasing focus of vendors on orphan drug products, and financial incentives provided by government in form of tax credits and waived FDA fees. For instance, the FDA grants a seven-year patent exclusivity to orphan drugs to treat a rare disease. Therefore, any other drug with the same indication cannot be approved by the FDA during these seven-years period. In addition, they also provide tax credits up to 50% of the total R&D cost after the drug receives the orphan drug designation. This credit can be used by the sponsor during the R&D phase of any drug irrespective of the drug designation. The orphan designated drugs are also exempted from paying the FDA fees. Thus, these financial incentives and grants for orphan drug attract many vendors to invest in developing drugs for rare diseases and make huge profits.
Technavios analysts forecast the global orphan drugs market to grow at a CAGR of 10.20% during the period 2017-2021.
Request for Sample PDF of Premium Research Report with TOC: https://www.researchmoz.us/enquiry.php?type=S&repid=1059719
Covered in this report
The report covers the present scenario and the growth prospects of the global orphan drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavio's report, Global Orphan Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Browse more details @ https://www.researchmoz.us/global-orphan-drugs-market-2017-2021-report.html
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
Key market highlights
Pipeline analysis
PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 06: Regulatory approval
Orphan drug legislation
PART 07: Market segmentation by product type
Biologics
Non-biologics
PART 08: Geographical segmentation
Orphan drugs market in Americas
Orphan drugs market in EMEA
Orphan Drugs Market in APAC
PART 09: Decision framework
PART 10: Drivers and challenges
Market Drivers
Impact of drivers on key customer segments
Market Challenges
Impact of challenges on key customer segments
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
ABSTRACT
About Orphan Drugs
According to Orphan Drug Designation program of the US Food and Drug Administration (FDA), orphan diseases are defined as rare diseases that affects less than 2,00,000 Americans. The global orphan drugs market is expected to benefit from patent extensions like Orphan Drug Exclusivity (ODE), increasing focus of vendors on orphan drug products, and financial incentives provided by government in form of tax credits and waived FDA fees. For instance, the FDA grants a seven-year patent exclusivity to orphan drugs to treat a rare disease. Therefore, any other drug with the same indication cannot be approved by the FDA during these seven-years period. In addition, they also provide tax credits up to 50% of the total R&D cost after the drug receives the orphan drug designation. This credit can be used by the sponsor during the R&D phase of any drug irrespective of the drug designation. The orphan designated drugs are also exempted from paying the FDA fees. Thus, these financial incentives and grants for orphan drug attract many vendors to invest in developing drugs for rare diseases and make huge profits.
Technavios analysts forecast the global orphan drugs market to grow at a CAGR of 10.20% during the period 2017-2021.
Request for Sample PDF of Premium Research Report with TOC: https://www.researchmoz.us/enquiry.php?type=S&repid=1059719
Covered in this report
The report covers the present scenario and the growth prospects of the global orphan drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavio's report, Global Orphan Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Browse more details @ https://www.researchmoz.us/global-orphan-drugs-market-2017-2021-report.html
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
Key market highlights
Pipeline analysis
PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 06: Regulatory approval
Orphan drug legislation
PART 07: Market segmentation by product type
Biologics
Non-biologics
PART 08: Geographical segmentation
Orphan drugs market in Americas
Orphan drugs market in EMEA
Orphan Drugs Market in APAC
PART 09: Decision framework
PART 10: Drivers and challenges
Market Drivers
Impact of drivers on key customer segments
Market Challenges
Impact of challenges on key customer segments
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
No comments:
Post a Comment